Literature DB >> 33200254

Tooth extraction in mice administered zoledronate increases inflammatory cytokine levels and promotes osteonecrosis of the jaw.

Tomoya Soma1, Ryotaro Iwasaki1, Yuiko Sato2,3, Tami Kobayashi2,4, Satoshi Nakamura2, Yosuke Kaneko2, Eri Ito5, Hiroyuki Okada6, Hisato Watanabe6, Kana Miyamoto2,7, Morio Matsumoto2, Masaya Nakamura2, Seiji Asoda1, Hiromasa Kawana1,8, Taneaki Nakagawa1, Takeshi Miyamoto9,10,11,12.   

Abstract

INTRODUCTION: Osteonecrosis of the jaw (ONJ) occurring after invasive dental treatment often adversely affects patients' activities of daily living. Long-term administration of strong anti-bone resorptive agents such as bisphosphonates prior to invasive dental treatment is considered an ONJ risk factor; however, pathological mechanisms underlying ONJ development remain unclear.
MATERIALS AND METHODS: We developed an ONJ mouse model in which a tooth is extracted during treatment with the bisphosphonate zoledronate.
RESULTS: We observed induction of apoptosis in osteocytes, resulting in formation of empty lacunae in jaw bones at sites of tooth extraction but not in other bones of the same mice. We also observed elevated levels of inflammatory cytokines such as TNFα, IL-6 and IL-1 in jaw bone at the extraction site relative to other sites in zoledronate-treated mice. We also report that treatment in vitro with either zoledronate or an extract from Porphyromonas gingivalis, an oral bacteria, promotes expression of inflammatory cytokines in osteoclast progenitor cells. We demonstrate that gene-targeting of either TNFα, IL-6 or IL-1 or treatment with etanercept, a TNFα inhibitor, or a neutralizing antibody against IL-6 can antagonize ONJ development caused by combined tooth extraction and zoledronate treatment.
CONCLUSIONS: Taken together, the cytokine storm induced by invasive dental treatment under bisphosphonate treatment promotes ONJ development due to elevated levels of inflammatory cytokine-producing cells. Our work identifies novel targets potentially useful to prevent ONJ.

Entities:  

Keywords:  Bisphosphonate; Cytokine; Inflammation; Osteoclast; Osteocyte

Mesh:

Substances:

Year:  2020        PMID: 33200254     DOI: 10.1007/s00774-020-01174-2

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  52 in total

1.  Possible association between diabetes and bisphosphonate-related jaw osteonecrosis.

Authors:  Mogher Khamaisi; Eran Regev; Noam Yarom; Batia Avni; Eran Leitersdorf; Itamar Raz; Sharon Elad
Journal:  J Clin Endocrinol Metab       Date:  2006-12-19       Impact factor: 5.958

2.  Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy.

Authors:  Tilman D Rachner; Uwe Platzbecker; Dieter Felsenberg; Lorenz C Hofbauer
Journal:  Mayo Clin Proc       Date:  2013-04       Impact factor: 7.616

3.  Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw.

Authors:  Rebecca Anne Miksad; Kuan-Chi Lai; Thomas Benton Dodson; Sook-Bin Woo; Nathaniel Simon Treister; Omosalewa Akinyemi; Marian Bihrle; Guy Maytal; Meredith August; G Scott Gazelle; J Shannon Swan
Journal:  Oncologist       Date:  2011-01-06

4.  Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy.

Authors:  Efstathios Kastritis; Pelagia Melea; Tina Bagratuni; Ioannis Melakopoulos; Maria Gavriatopoulou; Maria Roussou; Magdalini Migkou; Evangelos Eleutherakis-Papaiakovou; Evangelos Terpos; Meletios A Dimopoulos
Journal:  Leuk Lymphoma       Date:  2017-06-11

5.  Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?

Authors:  Sven Otto; Matthias Tröltzsch; Vesna Jambrovic; Sappasith Panya; Florian Probst; Oliver Ristow; Michael Ehrenfeld; Christoph Pautke
Journal:  J Craniomaxillofac Surg       Date:  2015-04-10       Impact factor: 2.078

6.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

Authors:  Robert E Marx
Journal:  J Oral Maxillofac Surg       Date:  2003-09       Impact factor: 1.895

7.  Diabetes microvascular disease and the risk for bisphosphonate-related osteonecrosis of the jaw: a single center study.

Authors:  Shira Molcho; Avivit Peer; Tal Berg; Boris Futerman; Mogher Khamaisi
Journal:  J Clin Endocrinol Metab       Date:  2013-09-13       Impact factor: 5.958

8.  Diabetes mellitus and corticotherapy as risk factors for alendronate-related osteonecrosis of the jaws: a study in Wistar rats.

Authors:  Soraya A Berti-Couto; Ana Carolina U Vasconcelos; Júlia E Iglesias; Maria Antonia Z Figueiredo; Fernanda G Salum; Karen Cherubini
Journal:  Head Neck       Date:  2013-05-04       Impact factor: 3.147

9.  Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.

Authors:  Ana O Hoff; Béla B Toth; Kadri Altundag; Marcella M Johnson; Carla L Warneke; Mimi Hu; Ajay Nooka; Gilbert Sayegh; Valentina Guarneri; Kimberly Desrouleaux; Jeffrey Cui; Andrea Adamus; Robert F Gagel; Gabriel N Hortobagyi
Journal:  J Bone Miner Res       Date:  2008-06       Impact factor: 6.741

10.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; John Fantasia; Reginald Goodday; Tara Aghaloo; Bhoomi Mehrotra; Felice O'Ryan
Journal:  J Oral Maxillofac Surg       Date:  2014-05-05       Impact factor: 2.136

View more
  6 in total

Review 1.  Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  J I Aguirre; E J Castillo; D B Kimmel
Journal:  Bone       Date:  2021-09-11       Impact factor: 4.398

2.  Osteonecrosis development by tooth extraction in zoledronate treated mice is inhibited by active vitamin D analogues, anti-inflammatory agents or antibiotics.

Authors:  Tomoya Soma; Ryotaro Iwasaki; Yuiko Sato; Tami Kobayashi; Eri Ito; Tatsuaki Matsumoto; Atsushi Kimura; Kana Miyamoto; Morio Matsumoto; Masaya Nakamura; Mayu Morita; Seiji Asoda; Hiromasa Kawana; Taneaki Nakagawa; Takeshi Miyamoto
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

3.  Porphyromonas gingivalis Induces Bisphosphonate-Related Osteonecrosis of the Femur in Mice.

Authors:  Shuxuan Wu; Feng Li; Jingjing Tan; Xiaoling Ye; Yushi Le; Nianke Liu; Vincent Everts; Qilong Wan
Journal:  Front Cell Infect Microbiol       Date:  2022-06-22       Impact factor: 6.073

Review 4.  Establishment and assessment of rodent models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  Ran Yan; Ruixue Jiang; Longwei Hu; Yuwei Deng; Jin Wen; Xinquan Jiang
Journal:  Int J Oral Sci       Date:  2022-08-10       Impact factor: 24.897

5.  Predictive Value of Neutrophil-Lymphocyte Ratio as a Marker in Antiresorptive Agent-Related Osteonecrosis of the Jaw: A Retrospective Analysis.

Authors:  Kazuto Kurohara; Kasumi Shimizu; Taku Murata; Gaku Koizumi; Akira Takigawa; Kokoro Nagata; Kenya Okumura; Naoya Arai
Journal:  Diagnostics (Basel)       Date:  2022-07-29

6.  Hao1 Is Not a Pathogenic Factor for Ectopic Ossifications but Functions to Regulate the TCA Cycle In Vivo.

Authors:  Atsushi Kimura; Akiyoshi Hirayama; Tatsuaki Matsumoto; Yuiko Sato; Tami Kobayashi; Satsuki Ikeda; Midori Maruyama; Mari Kaneko; Mayo Shigeta; Eri Ito; Tomoya Soma; Kana Miyamoto; Tomoyoshi Soga; Masaru Tomita; Akihito Oya; Morio Matsumoto; Masaya Nakamura; Arihiko Kanaji; Takeshi Miyamoto
Journal:  Metabolites       Date:  2022-01-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.